W
VRTX icon

Wealthfront’s Vertex Pharmaceuticals VRTX Stock Holding History

Wealthfront’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$1.25M Buy
6,487
+199
+3% +$35.4K 0.01% 210
2018
Q2 		$1.07M Sell
6,288
-4,985
-44% -$773K 0.01% 235
2018
Q1 		$1.84M Buy
11,273
+1,166
+12% +$190K 0.02% 146
2017
Q4 		$1.51M Buy
10,107
+1,584
+19% +$235K 0.02% 156
2017
Q3 		$1.3M Sell
8,523
-3
-0% -$452 0.02% 151
2017
Q2 		$1.1M Buy
8,526
+1,462
+21% +$176K 0.02% 142
2017
Q1 		$772K Buy
+7,064
New +$622K 0.01% 159
2016
Q4 		– Sell
-4,409
Closed -$385K – 401
2016
Q3 		$385K Sell
4,409
-331
-7% -$31.3K 0.01% 231
2016
Q2 		$408K Buy
+4,740
New +$410K 0.01% 200
2016
Q1 		– Sell
-3,447
Closed -$434K – 359
2015
Q4 		$434K Buy
3,447
+382
+12% +$46.1K 0.02% 160
2015
Q3 		$319K Sell
3,065
-1,140
-27% -$146K 0.01% 189
2015
Q2 		$519K Buy
4,205
+819
+24% +$103K 0.02% 104
2015
Q1 		$399K Buy
3,386
+641
+23% +$76.8K 0.02% 106
2014
Q4 		$326K Buy
2,745
+610
+29% +$68.7K 0.02% 110
2014
Q3 		$240K Buy
2,135
+495
+30% +$47.1K 0.02% 124
2014
Q2 		$162K Buy
1,640
+1,486
+965% +$104K 0.01% 133
2014
Q1 		$11K Buy
+154
New +$12.2K ﹤0.01% 489

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Wealthfront's VRTX Position: Q3 2018 in Review

Wealthfront increased its Vertex Pharmaceuticals (VRTX) stake by 3.2% in Q3 2018, buying an estimated $35.4K and bringing the position to 6,487 shares worth $1.25M. The position accounts for 0.01% of the portfolio, ranked #210.

Wealthfront first reported a position in VRTX in Q1 2014 and has held it in 17 quarters since. The position peaked at $1.84M in Q1 2018. 697 funds tracked by Wall St. Rank hold VRTX as of Q3 2018.

  • Wealthfront held 6,487 shares of Vertex Pharmaceuticals worth $1.25M as of Q3 2018.
  • Wealthfront bought 199 Vertex Pharmaceuticals shares in Q3 2018, an estimated $35.4K.
  • Vertex Pharmaceuticals made up 0.01% of Wealthfront's portfolio in Q3 2018, its #210 holding.
  • Wealthfront first reported a position in Vertex Pharmaceuticals in Q1 2014 and has held it in 17 quarters since.
  • Wealthfront's Vertex Pharmaceuticals position peaked at $1.84M in Q1 2018.
  • 697 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2018.

Based on Wealthfront's 13F filing for Q3 2018, filed 13 Nov 2018.